CAPE also suppresses PD-L1 expression induced by Epstein‒Barr virus latent membrane protein 1 (LMP1) in nasopharyngeal carcinoma (NPC), suggesting its potential use to block the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints in EBV-positive NPC patients [152]. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.